Dapagliflozin Improves Cardiovascular Outcomes in Patients With Poor Baseline Kidney Function and Type 2 Diabetes
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
JAMA Cardiology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Effect of Dapagliflozin on Cardiovascular Outcomes According to Baseline Kidney Function and Albuminuria Status in Patients With Type 2 Diabetes: A Prespecified Secondary Analysis of a Randomized Clinical Trial
JAMA Cardiol 2021 Apr 14;[EPub Ahead of Print], TA Zelniker, I Raz, O Mosenzon, JP Dwyer, HHJL Heerspink, A Cahn, EL Goodrich, K Im, DL Bhatt, LA Leiter, DK McGuire, JPH Wilding, I Gause-Nilsson, AM Langkilde, MS Sabatine, SD WiviottFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.